Results 31 to 40 of about 186,551 (294)
Fertility preservation in ovarian tumours [PDF]
, 2018 A considerable number of patients with a cancer diagnosis are of childbearing age and have not satisfied their desire for a family. Despite ovarian cancer (OC) usually occurring in older patients, 3%–14% are diagnosed at a fertile age with the overall 5 ...
Bardhi, E. +8 more
core +1 more source
Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?
Molecular Oncology, EarlyView.Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley +1 more source
Molecular Oncology, EarlyView.This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu +12 more
wiley +1 more source
A Series of Ovarian Neoplasms Mainly Malignant. [PDF]
BJOG: An International Journal of Obstetrics & Gynaecology, 1908 n ...
Bushneli, F. G., Kerrawalla, M. P.
openaire +3 more sources
Landscape of BRAF transcript variants in human cancer
Molecular Oncology, EarlyView.We investigate the annotation of BRAF variants, focusing on protein‐coding BRAF‐220 (formerly BRAF‐reference) and BRAF‐204 (BRAF‐X1). The IsoWorm pipeline allows us to quantify these variants in human cancer, starting from RNA‐sequencing data. BRAF‐204 is more abundant than BRAF‐220 and impacts patient survival.
Maurizio S. Podda +5 more
wiley +1 more source
Leydig Cell Tumour and Mature Ovarian Teratoma: Rare Androgen-Secreting Ovarian Tumours in Postmenopausal Women [PDF]
, 2016 Androgen-secreting ovarian tumours are extremely rare accounting for
Agapito, A +3 more
core +1 more source
Molecular Oncology, EarlyView.The pan‐HDAC inhibitor belinostat increases the expression of the pro‐apoptotic proteins Bim, Puma, and Noxa and induces apoptosis in ovarian cancer cell lines and patient‐derived tumor organoids when used at high concentrations. Moreover, inhibiting the anti‐apoptotic proteins Bcl‐xL or Mcl‐1 sensitizes these preclinical models to the cytotoxic effect
Cécilia Thomine +10 more
wiley +1 more source
EZH2 Single Nucleotide Variants (SNVs): Diagnostic and Prognostic Role in 10 Solid Tumor Types [PDF]
, 2017 The enhancer of zeste homolog 2 (EZH2) gene encodes a histone methyltransferase that is a catalytic subunit of the Polycomb repressive complex 2 (PRC2) group of proteins that act to repress gene expression.
Crea, Francesco +4 more
core +2 more sources
Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
Molecular Oncology, EarlyView.Fibroblasts, cells in the tumor environment, support ovarian cancer cell growth and alter morphology and drug response. We used fibroblast and cancer cell co‐culture models to test 528 drugs and discovered new drugs for combination treatment. We showed that adding Vorinostat or Birinapant to standard chemotherapy may improve drug response, suggesting ...
Greta Gudoityte +10 more
wiley +1 more source
Borderline ovarian neoplasms [PDF]
PONS - medicinski casopis, 2019 Borderline ovarian tumors are most commonly serous or mucinous and account for 1 to 15% of all epithelial tumors. These tumors are characterized by low malignant potential and are most often diagnosed when they reach a significant size, causing abdominal pain or distension of the abdomen.
Marijana Rakićević +6 more
openaire +1 more source